Which Product Type in the Allergy Care Market will Hold Larger Revenue Share Through 2027?

Worldwide prevalence of allergic ailments continues to rise, with growing sensitization rates to common allergens, particularly among children. In the U.S. alone, allergies are sixth-leading cause of chronic diseases, with an annual allergy healthcare cost of over US$ 18 billion, according to the Centers for Disease Control and Prevention (CDC).

Click here to Get Complete Synopsis of the Report – https://www.factmr.com/report/2382/allergy-care-market

A recent study of Fact.MR foresees allergy care market to continue on its steady trajectory, to exceed revenues worth US$ 5,500 Mn in 2018.
The allergy care market is expected to remain consolidated among Tier 1 players, who currently account for approximately 75% share. While these players are focusing on expansion in manufacturing facilities and strategic alliances with regional distributors, small and mid-sized players are eyeing partnerships with local players and strengthening their regional presence.

For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=2382

Allergy care medication sales will remain consolidated in drug & pharmacies stores, accounting for over 50% share in 2018. Availability of a wide variety of kits in drug stores, devoid of the need for prescription has further led affected individuals to buy medicines respective to their ailments from these stores. However, online retailers are fast gaining palpability in the allergy care market, enabling consumers to purchase their medication with the comfort of their home and at relatively affordable costs.

Revenues from Antihistamine Medication to be 1.5X of Nasal Spray

Antihistamine medication has traditionally been in high demand, with over US$ 2000 Mn worth sales estimated in 2018. Revenues from antihistamine medication is expected to be nearly 1.5X than those from nasal spray sales worldwide in 2018.

For critical insights on this market, request for methodology here - https://www.factmr.com/connectus/sample?flag=RM&rep_id=2382
 
Antihistamines have emerged as an effective medication to manage allergies such as urticarial, conjunctivitis, and rhinitis. Newer antihistamines introduced in the market are less sedative their traditional counterparts, and are deemed efficacious through head-to-head long-term studies.

GPs from leading healthcare institutes have been working on the assessment of allergy management support system’s (AMSS) feasibility for IgE-mediated allergy care. Effective development of an AMSS would further aid GPs in handling the increasing burden of managing allergic diseases, as well as facilitate diagnosis and treatment of various allergy-affected individuals. However, further research is essential for rolling out the technology on a full scale.

For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/2382/S

Emphasis on Telemedicine for Improving Clinical Outcomes

Healthcare specialists are focusing on allergies are using telemedicine in a bid to enhance clinical outcomes, and reduce travel issues associated with the affected individuals, according to the American College of Allergy, Asthma and Immunology (ACAAI). Designed for providing high-quality care, telemedicine services make effort to gather complete and accurate information clinical information of allergic patients.

For More Insights – https://www.globenewswire.com/en/news-release/2018/11/28/1658260/0/en/Drug-Pharmacies-Stores-Helm-Allergy-Care-Sales-Tier-1-Players-Hold-Nearly-75-Share-Fact-MR.html

Use of telemedicine for allergy care is expected to increase in line with broader application of telehealth in medicine. Several allergists currently perform initial visits by telemedicine for determining requirement of in-office testing. According to the ACAAI, telemedicine holds immense potential in reducing cost for immunologists and allergists alike.

A streamlined process for the multistate licensure is vital for expansion of the telemedicine allergy care. This would further facilitate access to specialty care, allow governments to retain regulatory authority and individual licensing. Current focus is on implementation of a standardized, explicit codes for enabling practitioners in seeking reimbursement for virtual encounters.

For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=2382

Scientists who study immune system have commenced understanding root cause of allergies, working on next-generation therapies to eliminate allergies right from their tracks. Several allergy therapies are becoming more specific and customizable with respect to patients.

Fact.MR’s study also offers an accurate forecast of the allergy care market for the period between 2018 and 2027. The study foresees the allergy care market to record an average CAGR of over 4% through 2027.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Content Source: https://www.factmr.com/media-release/765/allergy-care-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.